 |
 Video: What is a Stock Split?
|
|
|
| Werewolf Therapeutics is a biopharmaceutical company, engaged in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. Co. is utilizing its proprietary PREDATOR platform to design molecules that stimulate both adaptive and innate immunity with the aim of addressing the limitations of conventional proinflammatory immune therapies. Co.'s molecules, which it refers to as INDUKINE molecules, are intended to activate selectively in the tumor microenvironment. Co.'s product candidates, WTX-124 and WTX-330, are delivered, activated Interleukin-2 and Interleukin-12, respectively, INDUKINE molecules for the treatment of solid tumors. According to our Werewolf Therapeutics stock split history records, Werewolf Therapeutics has had 0 splits. | |
|
Werewolf Therapeutics (HOWL) has 0 splits in our Werewolf Therapeutics stock split history database.
Looking at the Werewolf Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Werewolf Therapeutics shares, starting with a $10,000 purchase of HOWL, presented on a split-history-adjusted basis factoring in the complete Werewolf Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
05/03/2021 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$16.26 |
|
| End price/share: |
$6.75 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-58.49% |
|
| Average Annual Total Return: |
-25.52% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$4,151.67 |
|
| Years: |
2.98 |
|
|
|
|
|
